In NSCLC patients, nivolumab’s objective response rate is 23.7%, significantly prolonging the overall survival, response rate, and progression-free survival (PFS) in patients in a manner independent of PD-L1 expression [337]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.